Anzeige
Mehr »
Montag, 18.08.2025 - Börsentäglich über 12.000 News
6,35-Mrd. vs. 30-Mio.-€ - Die Bewertungslücke im Kohlesektor, die kein Investor ignorieren kann
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
492 Leser
Artikel bewerten:
(2)

Royal Philips: Philips expands access to hemodynamics at point-of-care for real-time blood flow assessment on Handheld Ultrasound - Lumify


February 9, 2022

  • Philips point-of-care ultrasound technology now includes Pulse Wave Doppler for all physicians - from cardiologists and radiologists to emergency care - to quickly assess hemodynamics in cardiac function anytime, anywhere
  • Lumify is also the first and only handheld ultrasound with B-lines software and smart algorithms to enhance heart and lung assessment in severe COVID cases and more

Amsterdam, the Netherlands -Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has expanded its ultrasound portfolio with advanced hemodynamic assessment and measurement capabilities on its handheld point-of-care ultrasound - Lumify. With the addition of Pulse Wave Doppler [1], Philips has greatly expanded the utility of its Handheld Ultrasound - Lumify - enabling clinicians to quantify blood flow in a wide range of point-of-care diagnostic applications - including cardiology, vascular, abdominal, urology, obstetrics and gynecology. Also new to Lumify are obstetric measurements to help in early assessment of gestational age and the identification of high-risk pregnancies.

Point-of-care hemodynamics
Pulse Wave Doppler ultrasound provides clinicians with more information, in addition to 2D and color imaging, to assess hemodynamic patterns to differentiate between arterial and venous blood flow and quantify hemodynamic function. The resulting hemodynamic measurements can enhance diagnostic confidence and timely clinical decision-making in virtually any care setting, including cardiology and emergency medicine. With these latest features, Philips' easy-to-use fully integrated handheld ultrasound system - Lumify - brings together imaging tools across ultrasound platforms, leveraging the company's expertise in cardiology and radiology. The Lumify system also provides clinicians with advanced analysis software and reporting tools, and access to tele-ultrasound capabilities) for live communication support to connect clinicians around the globe for real-time collaboration.

"By applying Philips' expertise in cardiovascular care, imaging and patient monitoring to Philips Handheld Ultrasound - Lumify - we are committed to deliver a dedicated, innovative point-of-care portfolio, enabling clinicians to quickly assess hemodynamics - including cardiovascular function, organ perfusion and fetal assessment - in a daily routine, to identify abnormalities and intervene quickly," said Matthijs Groot Wassink, General Manager of Point of Care Ultrasound at Philips. "With the addition of Pulse Wave Doppler and enhanced obstetrics measurements, we have increased the number of markers on which diagnoses can be made, to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real-time."

"Having Color Flow Dopplerevaluation of acutely ill and injured patients in the Emergency Department in an upcoming webinar.

Philips B-lines software enhances heart and lung assessments in handheld ultrasound
In addition to adding Pulse Wave Doppler for hemodynamics, Philips is the first and only point-of-care ultrasound solution with B-lines (B-line quantification tool for ultrasound lung imaging) software and intelligent algorithms to enhance heart and lung assessments, which is critical when dealing with severe COVID cases. The pandemic has shown the relevance of lung ultrasound in the diagnosis and treatment of pneumonia, one of the most common complications of COVID-19. AI-enhanced automated algorithms looking for B-lines in lung fluid can help provide more objective data and interpretation.

Increased access to quality care
The continuous scanning, performance and portability of Philips Handheld Ultrasound - Lumify - brings a full diagnostic solution to care professionals at the bedside; both in and outside of the hospital. The innovative technology is also in widespread use in community-based mother and child care programs, providing access to quality healthcare for underserved communities worldwide, including a program in Kenyadriven by the Philips Foundationto educate midwives to deliver ultrasound-based antenatal pregnancy screening in village clinics, while receiving telehealth support from radiologists at distance.

For more information on the award-winning Philips Handheld Ultrasound - Lumify - and its tele-ultrasound capabilitiesfor the latest on high-quality portable imaging.

[1] Pulse Wave Doppler measurement is currently available on the Android Lumify app. Availability on the Apple iOS/ iPad iOS Lumify app is scheduled for the future.

For further information, please contact:

Kathy O'Reilly
Philips Global Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips.

Attachments

  • Man undergoing ultrasound in ED (https://ml-eu.globenewswire.com/Resource/Download/b3c4ccd2-88df-44a4-ab76-947a675a881b)
  • Product shot of Philips Lumify handheld ultrasound (https://ml-eu.globenewswire.com/Resource/Download/3919192d-c2eb-4876-8779-9034e2754f6b)

© 2022 GlobeNewswire (Europe)
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.